Prostate Cancer Biomarker And Treatment Research
What is this
This trend involves research on prostate cancer biomarkers and treatment, focusing on diagnostic tools like PSA levels and novel therapeutic approaches. It encompasses clinical studies and experimental therapies aimed at improving patient outcomes in prostate cancer care.
Why it matters
Prostate cancer remains one of the most common cancers among men, driving sustained investment in diagnostic and treatment innovations. Advances in biomarkers and targeted therapies could improve early detection and personalized treatment strategies, potentially reducing mortality rates.
Investment angle
Investors could look at biopharmaceutical companies developing novel diagnostics or targeted therapeutics for prostate cancer, as well as medical device companies involved in improved screening technologies. Additionally, companies involved in clinical trials and personalized medicine platforms present potential high-reward opportunities.
Compelling area in biotech with high potential if clinical breakthroughs occur, but layered with traditional R&D risks. Investability: 7/10.
History
| date | signals | new | substance |
|---|---|---|---|
| 2026-03-12 | 4 | 100% | |
| 2026-03-22 | 30 | +26 | 100% |
| 2026-04-02 | 32 | +2 | 100% |
| 2026-04-13 | 36 | +4 | 100% |
| 2026-04-24 | 46 | +10 | 100% |
| 2026-05-04 | 48 | +2 | 100% |
| 2026-05-16 | 50 | +2 | 100% |
| 2026-05-27 | 51 | +1 | 100% |
| 2026-06-06 | 52 | +1 | 100% |
| 2026-06-16 | 53 | +1 | 100% |
| 2026-06-27 | 54 | +1 | 100% |
| 2026-07-07 | 57 | +3 | 100% |
| 2026-07-18 | 59 | +2 | 100% |
| 2026-07-28 | 64 | +5 | 100% |
Evidence
- 2026-07-27ClinicalTrials.gov[EARLY_PHASE1] Preoperative Semaglutide Prior to Radical Prostatectomy · detail
- 2026-07-22ClinicalTrials.gov[PHASE1] Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy · detail
- 2026-07-21PubMedAn Integrative Methylation-Metabolism Gene Signature Defines Prognosis and Immunosuppressive Microenvironment in Prostate Cancer. · detail
- 2026-07-19NIH RePORTEROptimizing prostate cancer screening among older men · detail
- 2026-07-19NIH RePORTERIdentifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches · detail
- 2026-07-16PubMedMicroRNA-based diagnosis and therapy in prostate cancer. · detail
- 2026-07-09ClinicalTrials.gov[PHASE2] IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy · detail
- 2026-07-02PubMedCuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy. · detail
- 2026-06-28NIH RePORTERGenomic and Genomic Variation in Prostate Cancer · detail
- 2026-06-28NIH RePORTERIntegration of Life Expectancy Estimates into Electronic Health Record Decision Support for Men with Prostate Cancer · detail
- 2026-06-17ClinicalTrials.gov[PHASE3] A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation · detail
- 2026-06-08PubMedMetformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines. · detail
- 2026-05-31NIH RePORTERProject 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis · detail
- 2026-05-17NIH RePORTERA novel chemical strategy to harness the tumor specific biochemistry of human kallikrein 2 for prostate cancer theranostics · detail
- 2026-05-14ClinicalTrials.gov[PHASE2] Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance · detail
- 2026-05-04ClinicalTrials.gov[PHASE3] Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial · detail
- 2026-05-01ClinicalTrials.gov[PHASE2] A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer · detail
- 2026-04-24ClinicalTrials.gov[] Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies · detail
- 2026-04-22ClinicalTrials.gov[PHASE1] Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression · detail
- 2026-04-21ClinicalTrials.gov[PHASE1] A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread · detail